Last reviewed · How we verify

Védrines, Philippe, M.D. — Portfolio Competitive Intelligence Brief

Védrines, Philippe, M.D. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
addition of azathioprine addition of azathioprine marketed Purine analog immunosuppressant Inosine monophosphate dehydrogenase (IMPDH), hypoxanthine-guanine phosphoribosyltransferase (HGPRT) Immunology
Switch to a second anti-TNF drug alone Switch to a second anti-TNF drug alone marketed TNF inhibitor (class-level; specific agent varies) TNF-alpha Immunology / Rheumatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. PIBD-Net · 1 shared drug class
  2. University Hospital Schleswig-Holstein · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Védrines, Philippe, M.D.:

Cite this brief

Drug Landscape (2026). Védrines, Philippe, M.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/v-drines-philippe-m-d. Accessed 2026-05-18.

Related